Table 1

Participant demographic and clinical characteristics.

n = 1517
Age, yrs55.1 ± 11.7
Female1340 (88.3)
White1358 (89.5)
Hispanic75 (4.9)
Rurala214/1454 (14.1)
Autoimmune conditions
      RA925 (61.0)
      PsA299 (19.7)
      AS185 (12.2)
      SLE108 (7.1)
Medications
      bDMARD790 (52.1)
      JAK inhibitor158 (10.4)
      Methotrexate946 (62.4)
      Hydroxychloroquine537 (35.4)
      Glucocorticoids402 (26.5)
      NSAID373 (24.6)
Comorbidities
      Hypertension621 (40.9)
      Lung disease518 (34.2)
      DM179 (11.8)
      Heart disease121 (8.0)
      Kidney disease80 (5.3)
      Malignancy33 (2.2)
      Current smoking141 (9.3)
      PROMIS Anxiety, T-scoreb59.8 ± 8.5
  • Values are n (%) or mean ± SD.

  • aRural status shown among participants with available zip code.

  • bPROMIS Anxiety short form with range of 1-100, US adult population (mean 50 ± SD 10). AS: ankylosing spondylitis; bDMARD: biologic disease-modifying antirheumatic drug; DM: diabetes mellitus; JAK: Janus kinase; NSAID: nonsteroidal antiinflammatory drug; PsA: psoriatic arthritis; PROMIS: Patient-Reported Outcomes Measurement Information System; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus.